UCB considers partner for lung cancer drug CDP791; reports ‘positive’ phase 2
UCB SA. said it considering finding a partner for the development of its lung cancer drug CDP791 and reported ‘positive’ trends from second phase clinical trials.
This entry was posted on Monday, March 31st, 2008 at 8:09 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.